Altimmune (ALT) announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company’s President and CEO effective January 1, 2026. Altimmune’s Chairman of the Board, Jerry Durso, will assume the role of President and CEO and retain his position as Chairman. To facilitate a smooth transition, Dr. Garg will serve as an advisor to the Company through June 30, 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune announces publication of IMPACT Phase 2b trial data
- Altimmune announce results from analysis of biopsies from IMPACT Phase 2b trial
- Altimmune price target lowered to $14 from $15 at Citizens JMP
- Altimmune Reports Q3 2025 Financial and Business Progress
- Altimmune’s Earnings Call: Financial Growth and Clinical Progress